List of Perseris Kit drug patents

Perseris Kit is owned by Indivior Inc.

Perseris Kit contains Risperidone.

Perseris Kit has a total of 9 drug patents out of which 0 drug patents have expired.

Perseris Kit was authorised for market use on 27 July, 2018.

Perseris Kit is available in for suspension, extended release;subcutaneous dosage forms.

Perseris Kit can be used as administration of risperidone, method of treating schizophrenia, treatment of schizophrenia, treating schizophrenia.

The generics of Perseris Kit are possible to be released after 13 February, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406160 INDIVIOR INC Sustained release small molecule drug formulation
Jun, 2026

(3 years from now)

US10058554 INDIVIOR INC Sustained release small molecule drug formulation
Sep, 2026

(3 years from now)

US9597402 INDIVIOR INC Sustained release small molecule drug formulation
Sep, 2026

(3 years from now)

US11110093 INDIVIOR INC Sustained release small molecule drug formulation
Nov, 2026

(3 years from now)

US10010612 INDIVIOR INC Sustained delivery formulations of risperidone compounds
Feb, 2028

(5 years from now)

US10376590 INDIVIOR INC Sustained delivery formulations of risperidone compound
Feb, 2028

(5 years from now)

US9186413 INDIVIOR INC Sustained delivery formulations of risperidone compounds
Feb, 2028

(5 years from now)

US9180197 INDIVIOR INC Sustained delivery formulations of risperidone compounds
Feb, 2028

(5 years from now)

US11013809 INDIVIOR INC Sustained delivery formulations of risperidone compound
Feb, 2028

(5 years from now)

Drugs and Companies using RISPERIDONE ingredient

Market Authorisation Date: 27 July, 2018

Treatment: Method of treating schizophrenia; Administration of risperidone; Treating schizophrenia; Treatment of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic